Arcosa (ACA) Stock Forecast and Price Target (2026)

Last updated November 2026

Short answer

There is no meaningful price-target consensus for Arcosa (ACA): too few analysts publish a target on it for an average to mean anything. Thin coverage is normal for smaller and newer companies and says nothing about the business. What does exist is an earnings forecast. For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on ACA expect earnings of $4.31 per share (-3.6% on the year before) and revenue of $2.6 billion (-10%). The full quarter and fiscal-year estimates are below, with the drivers and risks that decide whether they are met. Walnut is not an investment adviser.

Why ACA has no consensus price target

Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. ACA is one of them. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model.

Operating multiples matter less than usual here because the CRH offer sets the price: at $147.01 the stock sits about 2% below the $150 cash consideration, a spread that pays holders for waiting until the expected first-quarter 2027 close and for the risk the deal breaks. Fiscal 2025 remains the cleanest reference point for the business itself, with revenue of roughly $2.88 billion and EPS of about $4.24, since 2026 results include the barge gain. The dividend is nominal at $0.20 a share a year (declared again in September), a yield near 0.14 percent, and full-year guidance stays withdrawn.

ACA earnings and revenue forecast

For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on ACA expect earnings of $4.31 per share (-3.6% on the year before) and revenue of $2.6 billion (-10%).

PeriodEPS estimateEPS growthRevenue estimateRevenue growth
Quarter ending Sep 2026
next quarter to report, 3 analysts
$1.57
$1.53 to $1.59
+0.6%$720 million
$717.1 million to $724.5 million
-9.8%
Quarter ending Dec 2026
the quarter after, 3 analysts
$0.99
$0.93 to $1.06
-14%$638.7 million
$635.8 million to $643 million
-11%
Fiscal year ending Dec 2026
fiscal year next to report, 3 analysts
$4.31
$4.16 to $4.46
-3.6%$2.6 billion-10%
Fiscal year ending Dec 2027
the fiscal year after, 3 analysts
$4.91
$4.75 to $5.08
+14%$2.8 billion
$2.8 billion to $3 billion
+9.6%

Consensus estimates for ACA published by sell-side analysts, as of November 2026, from Yahoo Finance. Each figure is the average of the analysts counted, with the lowest and highest estimate beneath it; growth compares with the same period a year earlier and is left blank where either figure is a loss. Estimates change constantly. Walnut is not an investment adviser.

Estimates are the most widely published forecast there is: many more analysts model a company's earnings than publish a price target on it. They are also revised constantly, and the direction of those revisions into a report is often more informative than the level. Arcosa next reports around October 29, 2026 (an estimated date), which is when these figures get tested against actual results.

Is there a 2030 forecast for ACA?

Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering ACA do not put out a 2030 number. Anything presenting one is extrapolating a growth rate of its own, and a figure produced that way tells you about the assumption chosen, not about the company.

The furthest-out consensus that exists is for the fiscal year ending Dec 2027: analysts expect earnings of $4.91 per share, +14% on the fiscal year ending Dec 2026 estimate of $4.31. Beyond that, nobody publishes estimates, so any later number is an extrapolation.

On the figures we hold as of November 2026, ACA trades at about 36.8 times trailing earnings and 30.4 times forward earnings. A forward multiple below the trailing one means the market expects earnings to grow, and the size of that gap is roughly how much growth is already in the price.

For a ten-year question, that frame is more useful. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Arcosa can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.

What could move ACA from here

In short: the drivers cited most often are The CRH merger sets the price, Aggregates pricing over volume, Utility structures backlog versus wind tower softness. The risk cited most often against it is the largest risk is deal failure.

Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the ACA is it a buy page.

Your questions about Arcosa

Ask Walnut's AI anything about ACA and see how it fits what you own.

FAQ

What is the price target for Arcosa (ACA)?

+

There is no meaningful consensus price target for ACA, because too few analysts publish on it. Thin coverage is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.

Is there an analyst forecast for ACA?

+

For earnings, yes; for the share price, not a meaningful one. For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on ACA expect earnings of $4.31 per share (-3.6% on the year before) and revenue of $2.6 billion (-10%). Fewer analysts publish a price target on ACA than publish earnings estimates, which is common for smaller and newer companies, and a lack of target coverage says nothing about the business itself.

What are analysts' earnings estimates for Arcosa (ACA)?

+

For the fiscal year ending Dec 2026, the 3 analysts publishing estimates on ACA expect earnings of $4.31 per share (-3.6% on the year before) and revenue of $2.6 billion (-10%). For the fiscal year ending Dec 2027, the consensus is $4.91 per share, +14% on the year before. These are consensus estimates as of November 2026, the average of what the covering analysts publish, and they are revised constantly, especially around each earnings report. They describe expectations, not results.

When does ACA report earnings next?

+

Arcosa's next earnings report is expected around October 29, 2026, a date estimated from its reporting history that the company has not yet confirmed. The report is when the estimates on this page get tested against actual results, which is why targets and estimates tend to move most in the days after it.

What could move ACA?

+

The drivers and the risks are laid out on this page and in more depth on the ACA "is it a buy" page. Without analyst estimates to anchor to, the useful framing is a set of scenarios.

Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a November 2026 data pull of published third-party research, are approximate, and change constantly. The share price is the last one Yahoo Finance reported on October 22, 2026, and every percentage against it on this page is measured from that price. Verify current figures with your broker before acting on them.

Forecasts for similar stocks